Kevin Alexander (@KMAlexanderMD) profile picture

Physician-scientist, advanced heart failure and transplant cardiologist, amyloidosis specialist

Stanford, CA
Joined April 2018
Photo by Kevin Alexander (@KMAlexanderMD)Photo by Kevin Alexander (@KMAlexanderMD)Photo by Kevin Alexander (@KMAlexanderMD)
Milestone reached!🫀 Today, @StVincentIN celebrated our 500th HeartMate 3 LVAD implant—500 lives transformed and 500 families given renewed hope. Grateful for our entire incredible MCS team and resilient patients! It takes a village! @shwinner @KayMorrisMong @AnotherAPatelMD
4
6
1
28
1,959
Proud to share our newly published study in the Journal of Echocardiography! In CA, MCF ≤25% was independently associated with higher mortality (adjusted HR 5.46; p=0.006). Promising findings that warrant further validation. 🔗 doi.org/10.1007/s12574-026-0…
1
3
12
570
Kevin Alexander retweeted
Looking forward to being part of this at HFSA
🫀 ATTR-CM can be overlooked or diagnosed late. Learn to recognize common clinical scenarios, apply evidence-based treatment across disease stages, and explore emerging therapies. 🔬 #HFSA2026 👉 Save your spot: mdsc.pe/4xZqxAn
2
11
433
Kevin Alexander retweeted
#Myeloma Paper of the Day: Transcriptome analysis of AL #amyloidosis pt myocardial samples finds upregulation of fibroblast activation genes (e.g. collagen type I/III & periostin), fibroblast-to-myofibroblast transition in vitro & matrix remodeling: pubmed.ncbi.nlm.nih.gov/4280…. #alsm
6
1
26
2,936
Now published in Heart Failure Reviews: Atrial fibrillation in ATTR-CM: marker of disease severity and implications for multidomain reassessment. Grateful to my co-authors for their collaboration and especially to Kevin M. Alexander, MD, for his guidance and valuable insights throughout this work. 🔗 rdcu.be/18UJsY5V1nVa #ATTRCM #CardiacAmyloidosis #AtrialFibrillation
1
6
10
809
Kevin Alexander retweeted
Observation in amyloidosis: Daratumumab can kill active plasma cells. Question: Can it help in pre-🫀 transplant desensitization? Answer: Yes! Excited to publish this study (a true labor of love!) in @JCardFail. onlinejcf.com/article/S1071-…
3
20
1
56
3,890
Kevin Alexander retweeted
Replying to @DorbalaSharmila
@DorbalaSharmila presented the results of the #REVEAL study - Evuzamitide PET/CT in cardiac amyloidosis Amazing results of this first ever rigorously conducted multicenter trial of an imaging agent in cardiac amyloidosis We are so thankful for the commitment of patients and investigators to the conduct of this investigator initiated trial. Simultaneously published in @JAMA_current jamanetwork.com/journals/jam… #cardiotwitter #ESC2026 #ESCCongress #ESCCongress2026 #ESCCongressMedIQ
2
33
1
75
3,114
Paper out: "Persistent Primary Graft Dysfunction Stratifies Risk After Heart Transplantation w/Lower Mortality Among Recipients of Donation-After-Circulatory-Death Hearts” by Alexander Berg, @JW_MacArthur, et al✨ @aravindkrishnan @ElbertHeng @AliceLiZhou ow.ly/Vpij50ZBBhy
3
5
702
The p.Val142Ile (Val122Ile) variant is the most common hereditary ATTR amyloidosis mutation in the U.S., disproportionately affecting individuals of African ancestry. This review highlights ongoing challenges in timely diagnosis, genetic screening, access to specialty care, and equitable treatment, while outlining priorities to improve outcomes through earlier identification, multidisciplinary care, and more inclusive clinical trials. A timely and important read (link.springer.com/article/10…) #HREV @senthil_selv @KMAlexanderMD @NotNoninvasive
4
7
541
Kevin Alexander retweeted
In ATTR-CM, atrial fibrillation is present in the majority of patients. The ATTRibute-CM trial showed that 69% of participants had AF at baseline, and many went on to experience new or worsening AF events during follow-up. With patients living longer, the clinical burden of arrhythmias is becoming a central part of ATTR-CM management. AF is not only common but is associated with more advanced disease, higher NT-proBNP, worse functional status, and increased hospitalizations. Our post-hoc analysis published in @JCardFail found that acoramidis reduced the frequency of recurrent new or worsening AF events by 26% versus placebo over 30 months, independent of baseline AF. There was also a numerical reduction in adjudicated AF-related cardiovascular hospitalizations with acoramidis. These data add to the growing evidence that disease-modifying therapy can favorably impact multiple aspects of ATTR-CM beyond the primary heart failure endpoints. onlinejcf.com/article/S1071-…
3
21
48
3,106
Kevin Alexander retweeted
With awareness of #ATTR growing, what do electrophysiologists need know about its cardiac manifestation & related conditions like atrial fibrillation? Watch this MasterClass w/ Drs Kevin M Alexander & Eoin Donnellan to learn: bit.ly/4pIJgwK #HRS2026 @KMAlexanderMD
3
7
259
Kevin Alexander retweeted
Huge thanks to @EoinDonnellan1 & @KMAlexanderMD for an insightful discussion at #HRS2026! Key clinical insights, practical applications, and real-world relevance throughout. 📺 Watch the replay: bit.ly/26ATTR-CA-T With appreciation to @BridgeBioPharma for grant support! #CME #MedEd
3
6
425
Excellent @PeerView session today on Electrophysiologic Insights into ATTR-CM with @KMAlexanderMD & Dr. Eoin Donnellan. Asked about AF as a marker of advanced disease vs independent driver of mortality — same signal we observed in our Cuban ATTR-CM cohort: 🫀 AF tracked disease severity 🫀 Lost significance after multivariable adjustment #CardioAmyloidosis #CardioTwitter #ATTRCM
3
10
385
Kevin Alexander retweeted
🌟 Join PeerView Live at McCormick Place Convention Center (Room S103)—or virtually—during #HRS2026! Starting at 11:30AM CDT, hear from @KMAlexanderMD & @EoinDonnellan1 on managing atrial fibrillation in transthyretin cardiac #amyloidosis. Register: bit.ly/26ATTR-CA-T #MedEd
3
5
219
Kevin Alexander retweeted
🫀 ATTR-CA. Don’t miss it. Don’t miss THIS. ⚡ Live EP insights. Real-world strategies. Immediate impact. Join @PeerView at #HRS2026 with @KMAlexanderMD & Eoin Donnellan, MD 📅 4/23 | ⏰ 11 AM CDT 🎯 Show up. Level up Seeing you 🫵 there‼️ Register 👉 bit.ly/26ATTR-CA-T
5
6
202
Kevin Alexander retweeted
Expand your treatment toolbox for managing atrial fibrillation in patients with transthyretin cardiac #amyloidosis with @KMAlexanderMD ➡️ 4/23 at 11:00 AM CDT: bit.ly/26ATTR-CA-T #HRS2026 #EPeeps #cardiology #MedEd
2
4
193
Kevin Alexander retweeted
Editorial comment by @KMAlexanderMD and I on how can focus on the root causes of these trends with strategies to consider for HF prevention, ambulatory care, enterprise level approaches in managing patients with chronic HF @JACCJournals 🔗 jacc.org/doi/10.1016/j.jchf.…
1
9
15
1,328
Kevin Alexander retweeted
Join Kevin M. Alexander, MD, FACC, FHFSA (@KMAlexanderMD), & Eoin Donnellan, MD, on 4/23 at 11:00 AM CDT during #HRS2026 for an #ATTR #MedEd event ➡️ bit.ly/26ATTR-CA-T #EPeeps #cardiology #amyloidosis #MedEd
2
7
212